2012 Results - Essilor

More documents

Recommendations

Info

Understanding Light’s Crucial Role in Everyday Health Most of visible light is essential & beneficial › Acuity › Color perception › Pupillary reflex › Control of non-visual functions (circadian rhythm) Part of the light spectrum is harmful and even toxic › UV can cause crystalline lens opacity & cataract (possible surgery) › Blue light can cause retinal cell damage & AMD (no curative solution) NON-VISIBLE UV 280nm 380nm BLUE 500nm VISIBLE 780nm 2012 Results 44
Essilor’s Long-term EYE HEALTH Defense Program 4 years ago, Essilor & Paris Vision Institute (IdV)* partnership embarked on a long-term eye health program The 1 st ever biological in vitro tests in the ophthalmic industry were conducted to identify the most toxic wavelengths in blue light: - Unique cell illumination system: narrow bands, natural sunlight retinal exposure. - Phototoxicity model with primary retinal cells. - Rigorous photometric protocol, etc… * Based in Paris, and linked to Pierre & Marie Curie University, IdV is considered as one of Europe's foremost integrated research Centers of Excellence on eye diseases and vision. Researchers, medical doctors and industry players work together for the discovery and clinical evidence of new therapeutic approaches and preventive solutions, as well as innovative compensatory technologies for vision impairments. 2012 Results 45
Page 1 and 2: 2012 Results February 28, 2013
Page 4 and 5: 2012: A Year of Acceleration 2012 R
Page 6 and 7: 2012: Step-up in Revenues from Fast
Page 8 and 9: Leveraging the Power of Partnership
Page 10 and 11: Strategy Delivering Consistent and
Page 12 and 13: Revenue Up 19.1% to €4,989m In
Page 14 and 15: Q4 Revenue Up 10.5% at Constant Exc
Page 16 and 17: Positive Contribution from All Regi
Page 18 and 19: 24 Bolt-on Acquisitions (1) Represe
Page 20 and 21: Fast-Growing Markets (1) : On Track
Page 22 and 23: Impact of PPA and Acquisition Costs
Page 24 and 25: Profit Attributable to Equity Holde
Page 26 and 27: Investing in New Capacity to Suppor
Page 28 and 29: Strong Financial Position In € mi
Page 30 and 31: Transitions: Background to discussi
Page 32 and 33: Agenda Introduction Operational and
Page 34 and 35: Many New Fields of Research… Pers
Page 36 and 37: … And Highly Promising Innovation
Page 38 and 39: … And Still Many Challenges to Me
Page 40 and 41: 40 TM
Page 42 and 43: People Can Now Live 100 Years, BUT
Page 46 and 47: After 2 Years of Photobiology Cell
Page 48 and 49: A New Technology Allowing SELECTIVE
Page 50 and 51: 2 Strategic Targets for Blue-Violet
Page 52 and 53: Launch Strategy of April 2013: Cou
Page 54 and 55: Crizal ® Prevencia: A New Step For
Page 56 and 57: Agenda Introduction Operational and
Page 58 and 59: Optical Market: An Accelerating Gro
Page 60 and 61: Need for Vision Correction is Incre
Page 62 and 63: Product Mix is Changing Rapidly Pro
Page 64 and 65: A Further 1.4 Billion People Will C
Page 66 and 67: A Fragmented Industry where Consoli
Page 68 and 69: Catch-Up Supporting Growth of the U
Page 70 and 71: Improving Distribution Networks & A
Page 72 and 73: Key Areas of Focus for 2013 Talent
Page 77 and 78: Gaining Share through Market Consol
Page 83: Leveraging our Strengths in Develop
Page 89 and 90: 2000 2001 2002 2003 2004 2005 2006
Page 91: 53,000 People and a Unique Entrepre

2012 Results - Essilor

Create successful ePaper yourself

Delete template?

Save as template?